AGFA-GEVAERT NV (AGFB.BR)

BE0003755692 - Common Stock

1.178  +0.02 (+1.9%)

Fundamental Rating

2

Taking everything into account, AGFB scores 2 out of 10 in our fundamental rating. AGFB was compared to 13 industry peers in the Health Care Technology industry. While AGFB seems to be doing ok healthwise, there are quite some concerns on its profitability. AGFB is valued expensive and it does not seem to be growing.



0

1. Profitability

1.1 Basic Checks

AGFB had negative earnings in the past year.
AGFB had a negative operating cash flow in the past year.
AGFB had negative earnings in 4 of the past 5 years.
In the past 5 years AGFB reported 4 times negative operating cash flow.

1.2 Ratios

AGFB has a Return On Assets of -4.01%. This is in the lower half of the industry: AGFB underperforms 66.67% of its industry peers.
AGFB's Return On Equity of -14.47% is on the low side compared to the rest of the industry. AGFB is outperformed by 75.00% of its industry peers.
Industry RankSector Rank
ROA -4.01%
ROE -14.47%
ROIC N/A
ROA(3y)-6.95%
ROA(5y)0.93%
ROE(3y)-23.67%
ROE(5y)-5.43%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

In the last couple of years the Operating Margin of AGFB has declined.
Looking at the Gross Margin, with a value of 30.71%, AGFB is doing worse than 75.00% of the companies in the same industry.
In the last couple of years the Gross Margin of AGFB has remained more or less at the same level.
AGFB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 30.71%
OM growth 3Y-17.71%
OM growth 5Y-24.95%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.5%
GM growth 5Y-0.57%

4

2. Health

2.1 Basic Checks

AGFB does not have a ROIC to compare to the WACC, probably because it is not profitable.
AGFB has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for AGFB has been reduced compared to 5 years ago.
Compared to 1 year ago, AGFB has a worse debt to assets ratio.

2.2 Solvency

AGFB has an Altman-Z score of 2.18. This is not the best score and indicates that AGFB is in the grey zone with still only limited risk for bankruptcy at the moment.
AGFB has a Altman-Z score (2.18) which is comparable to the rest of the industry.
AGFB has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
AGFB's Debt to Equity ratio of 0.21 is in line compared to the rest of the industry. AGFB outperforms 50.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Altman-Z 2.18
ROIC/WACCN/A
WACC9.25%

2.3 Liquidity

AGFB has a Current Ratio of 1.96. This is a normal value and indicates that AGFB is financially healthy and should not expect problems in meeting its short term obligations.
AGFB has a better Current ratio (1.96) than 66.67% of its industry peers.
A Quick Ratio of 1.15 indicates that AGFB should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.15, AGFB is in line with its industry, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.96
Quick Ratio 1.15

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 79.20% over the past year.
The Revenue for AGFB has decreased by -33.65% in the past year. This is quite bad
AGFB shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -12.10% yearly.
EPS 1Y (TTM)79.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.44%
Revenue 1Y (TTM)-33.65%
Revenue growth 3Y-12.37%
Revenue growth 5Y-12.1%
Sales Q2Q%-7.41%

3.2 Future

Based on estimates for the next years, AGFB will show a very strong growth in Earnings Per Share. The EPS will grow by 31.13% on average per year.
AGFB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.03% yearly.
EPS Next Y74.5%
EPS Next 2Y42.96%
EPS Next 3Y31.13%
EPS Next 5YN/A
Revenue Next Year-1.04%
Revenue Next 2Y1.07%
Revenue Next 3Y2.03%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AGFB. In the last year negative earnings were reported.
AGFB is valuated quite expensively with a Price/Forward Earnings ratio of 57.75.
AGFB's Price/Forward Earnings ratio is in line with the industry average.
When comparing the Price/Forward Earnings ratio of AGFB to the average of the S&P500 Index (19.80), we can say AGFB is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 57.75

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AGFB indicates a rather cheap valuation: AGFB is cheaper than 83.33% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 6.88

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
AGFB's earnings are expected to grow with 31.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.96%
EPS Next 3Y31.13%

0

5. Dividend

5.1 Amount

No dividends for AGFB!.
Industry RankSector Rank
Dividend Yield N/A

AGFA-GEVAERT NV

EBR:AGFB (5/30/2024, 4:55:44 PM)

1.178

+0.02 (+1.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap182.38M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 57.75
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.01%
ROE -14.47%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 30.71%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.96
Quick Ratio 1.15
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)79.2%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y74.5%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-33.65%
Revenue growth 3Y-12.37%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y